<DOC>
	<DOC>NCT01107886</DOC>
	<brief_summary>The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications</brief_summary>
	<brief_title>Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications</brief_title>
	<detailed_description>A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus HbA1c â‰¥6.5%. (based on the last measured and documented laboratory measurement within 6 months) High risk for CV events Established cardiovascular disease and/or multiple risk factors Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP1 mimetics Acute vascular event &lt;2months prior to randomisation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Risk of cardiovascular disease and death in patients with type 2 diabetes mellitus</keyword>
</DOC>